NCT07213310

Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults

A Phase 1, Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 on the Pharmacokinetics of DWP16001 and Its Metabolite in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults

Detailed description

A phase 1, open-label, fixed-sequence, drug-drug interaction study to evaluate the effect of DWC202511 or DWC202512 on the pharmacokinetics of DWP16001 and its metabolite in healthy adult subjects

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	DWP16001	DWP16001 enavogliflozin (single oral dose) is administered in accordance with the study protocol.
DRUG	DWC202511	Repeated oral administration of DWC202511 500 mg twice daily (BID), in accordance with the study protocol.
DRUG	DWC202512	Repeated oral administration of DWC202512 once daily, in accordance with the study protocol

Timeline

• Start date: 2025-11-09
• Primary completion: 2026-01-07
• Completion: 2026-01-07
• First posted: 2025-10-08
• Last updated: 2026-02-11

Locations

1 site across 1 country: South Korea